About Align Technology, Inc. - Common Stock (ALGN)
Align Technology is a medical device company known primarily for its innovative dental products, including the Invisalign system, which offers a clear alternative to traditional metal braces for orthodontic treatment. The company focuses on transforming patients' smiles through advanced 3D computer modeling and digital scanning technologies, enabling customized treatment plans. In addition to its flagship product, Align Technology also produces a range of other tools and software that enhance dental practice efficiency and patient care, serving both orthodontists and general dentists. By combining cutting-edge technology with a commitment to improving oral health, Align Technology aims to empower patients and revolutionize the field of orthodontics. Read More
Dental technology company Align Technology (NASDAQ:ALGN) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 1.8% year on year to $995.7 million. The company expects next quarter’s revenue to be around $1.04 billion, close to analysts’ estimates. Its non-GAAP profit of $2.61 per share was 8.4% above analysts’ consensus estimates.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top S&P500 gainers and losers shaping the post-market sentiment.
Align Technology's Q3 earnings show a mixed picture, beating EPS estimates with $2.61 while revenue was in-line. Clear aligner volume grew 4.9% year-over-year.
Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today reported financial results for the third quarter ("Q3'25"). Q3'25 total revenues were $995.7 million, down 1.7% sequentially and up 1.8% year-over-year. Q3'25 total revenues were favorably impacted by foreign exchange of approximately $11.7 million, or 1.2% sequentially, and favorably impacted by approximately $15.6 million, or 1.6% year-over-year.(1) Q3'25 Clear Aligner revenues were $805.8 million, up 0.1% sequentially and up 2.4% year-over-year. Q3'25 Clear Aligner revenues were favorably impacted by foreign exchange of approximately $9.8 million, or 1.2% sequentially, and favorably impacted by approximately $13.0 million, or 1.6% year-over-year.(1) Q3'25 Clear Aligner volume was up 0.5% sequentially and up 4.9% year-over-year. Q3'25 Imaging Systems and CAD/CAM Services revenues were $189.9 million, down 8.6% sequentially, and down 0.6% year-over-year. Q3'25 Imaging Systems and CAD/CAM Services revenues were favorably impacted by foreign exchange of approximately $1.8 million, or 1.0% sequentially and favorably impacted by approximately $2.6 million, or 1.4% year-over-year.(1)
Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software, today announced ClinCheck® Live Plan, a new feature in its Invisalign® digital treatment planning that automates the generation of initial doctor-ready treatment plans within 15 minutes. This advancement represents a major technological milestone in the Align™ Digital Platform, that can reduce the Invisalign treatment planning cycle from days to minutes.
Align Technology, Inc. (NASDAQ: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software, today announced a series of new product innovations for iTero™ Digital Solutions, a comprehensive ecosystem that includes intraoral scanners and integrated software tools that are designed to transform dental consultations into a modern, multi-modal oral health assessment that helps doctors and their teams deliver exceptional chairside experiences in support of Invisalign treatment conversion1. These new capabilities span across key practice workflows that underline the Align™ Digital Workflow including Diagnose, Plan, Treat, and Monitor steps. From dynamic and personalized visualization and patient engagement tools at chairside, to expanded compatibility with 3D printers and milling machines, these new innovations simplify workflows, increase patient acceptance1, and drive practice growth.2
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 13.6% gain for healthcare stocks has fallen short of the S&P 500’s 25.5% rise.
Align Technology’s stock price has taken a beating over the past six months, shedding 23% of its value and falling to $128.81 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
As the Q3 2025 earnings season unfolds, corporate America is delivering a powerful narrative of resilience and growth, significantly influencing overall stock market movements. Despite a complex backdrop of economic uncertainties and geopolitical tensions, stronger-than-expected corporate performances are largely driving a prevailing sense of optimism among investors. This robust earnings
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report third quarter 2025 financial results on Wednesday, October 29, 2025, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Align website at http://investor.aligntech.com.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Align (ALGN) To Contact Him Directly To Discuss Their Options
Align Technology, Inc. (NASDAQ: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today shared highlights from its 2025 Global Faculty Meeting, reinforcing its commitment to empowering doctors who use and educate their peers on Invisalign treatment techniques and Align digital tools including iTero scanners while advancing the orthodontic and dental profession.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Align Technology, Inc. (“Align” or the “Company”) (NASDAQ: ALGN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
